Yinxian Yang

Yinxian Yang

Auto-generated profile, based on publicly available information

Yinxian Yang

State Key Laboratory of Advanced Drug Delivery and Release Systems, School of Pharmacy, Zhejiang University, Hangzhou 310058, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
YYYinxian Yang
Yinxian Yang
BSBingjun Sun
Bingjun Sun
SZShiyi Zuo
Shiyi Zuo
XLXimu Li
Ximu Li
SZShuang Zhou
Shuang Zhou
JSJin Sun
Jin Sun
Trisulfide bond enhances the stability and GSH sensitivity of doxorubicin dimeric prodrug nanoassemblies.

27 November 2024 in Science Translational Medicine
Verified
Journal Article
Closed access
SZSheng Zhao
Sheng Zhao
ZLZiyi Lu
Ziyi Lu
RCRuisi Cai
Ruisi Cai
HWHui Wang
Hui Wang
SGShukun Gao
Shukun Gao
ZGZhen Gu
Zhen Gu
The maintenance of stable plasma drug concentrations within a therapeutic window can be critical for drug efficacy. Here, we developed a wearable osmotic microneedle (OMN) patch to support sustained drug dosing for at least 24 hours without the use of electronic components. The OMN patch uses an osmotic pressure driving force to deliver drug solution into the skin through three hollow microneedles with diameters of less than 200 micrometers. The rate of drug release was related to the composition and concentration of the osmogen and drug and to the physical properties of the semipermeable membrane separating the low- and high-solute compartments. The OMN patch released the peptide drug exenatide in rats and mice for 24 hours, whereas subcutaneous injection resulted in a burst release and rapid decline in the plasma drug concentration. OMN release of exenatide improved glycemic control in a diabetic mouse model consistent with a sustained effective plasma concentration of the drug. Continuous release of the small-molecule chemotherapeutic drug cytarabine reduced the progression of acute myeloid leukemia in mice more effectively than subcutaneous injection. Further evaluation of the OMN patch in canines demonstrated continuous dosing of cytarabine up to 225 milligrams for 24 hours, satisfying clinical requirements (150 to 300 milligrams daily). OMN patches were well tolerated in human participants with minimal pain or irritation of the skin and a stated preference over other administration routes. This wearable drug delivery system could provide a platform for stable high-dose drug release with convenience and safety.

10 June 2025 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
JHJinpeng Han
Jinpeng Han
SWShenqiang Wang
Shenqiang Wang
WFWeifeng Fang
Weifeng Fang
YYYinxian Yang
Yinxian Yang
RZRuyi Zhou
Ruyi Zhou
ZGZhen Gu
Zhen Gu

17 April 2026 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
SWShenqiang Wang
Shenqiang Wang
YYYinxian Yang
Yinxian Yang
YWYanfang Wang
Yanfang Wang
JHJinpeng Han
Jinpeng Han
THTong Hu
Tong Hu
ZGZhen Gu
Zhen Gu

11 February 2026 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
YYYinxian Yang
Yinxian Yang
SWShenqiang Wang
Shenqiang Wang
XSXueying Shi
Xueying Shi
XCXudong Chen
Xudong Chen
RZRuyi Zhou
Ruyi Zhou
ZGZhen Gu
Zhen Gu
Tumor-targeted delivery of oncolytic viruses (OVs) via systemic administration could not only expand virotherapy beyond primary tumors to widespread metastases, but also improve clinical adherence and convenience. We here engineer megakaryocytes encapsulating oncolytic adenovirus type 5 (M-Ad5) to produce oncolytic platelets in vivo by leveraging the thrombopoiesis process. Upon intravenous administration, M-Ad5 travels through the lungs, where it can release OVs-harbored therapeutic platelets into circulation under pulmonary turbulence microenvironments. Under the shelter of platelets, OVs resist inactivation by neutralizing antibodies and actively target widespread noninjectable cancer lesions. Intravenous infusion of M-Ad5 to mice with A549 lung cancer could significantly inhibit tumor growth and prolong survival. In multiple mouse tumor models, M-Ad5 induced a robust antitumor immune response by reprogramming the immunosuppressive tumor microenvironment, and potentiated the response to immune checkpoint inhibitors by recruiting more immune cells. We demonstrated that M-Ad5 in combination with PDL1 inhibitors activated tumor antigen-specific CD8 + T cells and memory T cells, thereby suppressing the growth of CT26 colorectal cancer metastasis, and preventing postsurgical B16F10 cancer recurrence and metastatic spread, as well as providing long-term immune protection against the rechallenged tumors.

1 July 2026 in Science Translational Medicine
Verified
Journal Article
Closed access
RZRuyi Zhou
Ruyi Zhou
DCDong Cen
Dong Cen
MCMingyu Chen
Mingyu Chen
JNJunjie Nan
Junjie Nan
JYJiahuan You
Jiahuan You
XCXiujun Cai
Xiujun Cai
Successful treatment of resectable intestinal diseases hinges on advanced intestinal anastomosis techniques and effective postoperative management. However, current postoperative adjuvant therapy remains limited to systemic administration of medications after conventional hand-sewn anastomosis, frequently leading to associated complications and potential recurrence. Here, we introduce a microneedle anastomotic stent (MAS) for postoperative intestinal healing and localized drug delivery in resectable intestinal diseases. This MAS integrates a biodegradable polyglycolic acid stent with a stimulus-responsive polyprodrug microneedle patch. This design provides robust mechanical properties, effective prevention of anastomotic leakage, and on-demand drug release at the anastomotic site. After intestinal resection, the MAS is implanted at the anastomotic site, where the microneedles penetrate the mucosal layer and release the anti-inflammatory drug in response to hyperinflammatory conditions, thereby attenuating local inflammation and facilitating anastomotic healing. In vitro assays verified the minimal cytotoxicity and good biocompatibility of the MAS and its degradation products. The efficacy of the MAS in tissue penetration and stimulus-responsive drug release was demonstrated using ex vivo patient samples. The in vivo therapeutic benefit and mechanism of the MAS were validated in the murine radiation colitis model, and its feasibility and safety were further confirmed in the minipig model of ischemic inflammatory injury. The MAS also exhibited versatility as a delivery platform for diverse therapeutics, suggesting potential applications in complex intestinal diseases. Compared with conventional methods, in preclinical studies, the MAS offered a sutureless approach for intestinal anastomosis and postoperative adjuvant therapy, holding potential for treating various resectable intestinal diseases.